Skip to main content

Table 6 SAIA-HTN economic evaluation summary

From: Systems analysis and improvement approach to optimize the hypertension diagnosis and care cascade for PLHIV individuals (SAIA-HTN): a hybrid type III cluster randomized trial

Perspective Payer (MOH) to determine incremental costs/net benefits of integrating SAIA-HTN into HIV chronic care. Societal to determine the incremental cost and benefits of integrating SAIA-HTN into HIV chronic care.
Cost estimates Intervention costs (SAIA-HTN delivery), medical costs averted and accrued of additional hypertensive PLHIV diagnosed with HTN, initiated on anti-hypertensive treatment, and retained in care.
Cost data collection Facility-level cost data collection on activities and resource use, including time motion studies for personnel time. Additional information collected on expenses from the SAIA-HTN budget, published secondary data on government information on civil servant salary costs, and medical supplies.
Primary outcomes Proportion of PLHIV patients 1) screened for HTN, 2) diagnosed with HTN, 3) initiating hypertension medications, 4) adherent to hypertension medications (via timely medication pick up), and 5) with controlled HTN, and DALYs averted.
Discounting A discounting rate of 3% will be used, and varied from 0% to 5% in sensitivity analyses [66].
Analytic time frame Using mathematical models estimating medium and long-term health outcomes, the ICER for progression through the HTN cascade for PLHIV and DALY averted will be reported over 1, 5, 10-, and 15-year time frames.